quilostigmine has been researched along with cymserine in 1 studies
| Studies (quilostigmine) | Trials (quilostigmine) | Recent Studies (post-2010) (quilostigmine) | Studies (cymserine) | Trials (cymserine) | Recent Studies (post-2010) (cymserine) |
|---|---|---|---|---|---|
| 7 | 1 | 1 | 12 | 0 | 4 |
| Protein | Taxonomy | quilostigmine (IC50) | cymserine (IC50) |
|---|---|---|---|
| Cholinesterase | Homo sapiens (human) | 0.2529 | |
| Acetylcholinesterase | Mus musculus (house mouse) | 8.4 | |
| Acetylcholinesterase | Homo sapiens (human) | 0.4808 | |
| Cholinesterase | Mus musculus (house mouse) | 0.24 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chaudhaery, SS; Nath, C; Nazir, A; Roy, KK; Sammi, SR; Saxena, AK; Saxena, G; Shakya, N | 1 |
1 other study(ies) available for quilostigmine and cymserine
| Article | Year |
|---|---|
Novel carbamates as orally active acetylcholinesterase inhibitors found to improve scopolamine-induced cognition impairment: pharmacophore-based virtual screening, synthesis, and pharmacology.
Topics: Acetylcholinesterase; Administration, Oral; Animals; Avoidance Learning; Caenorhabditis elegans; Carbamates; Catalytic Domain; Cholinesterase Inhibitors; Databases, Factual; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Male; Mice; Models, Molecular; Nootropic Agents; Quantitative Structure-Activity Relationship; Scopolamine | 2010 |